Top

Clinical and Translational Oncology

Published in:

01-03-2011 | Educational Series

Direct antitumour activity of zoledronic acid: preclinical and clinical data

Authors: Joaquim Bosch-Barrera, Sofía D. Merajver, Javier A. Menéndez, Catherine Van Poznak

Published in: Clinical and Translational Oncology | Issue 3/2011

Title: Direct antitumour activity of zoledronic acid: preclinical and clinical data
Authors: Joaquim Bosch-Barrera
Sofía D. Merajver
Javier A. Menéndez
Catherine Van Poznak
Publication date: 01-03-2011
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 3/2011
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-011-0634-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 3/2011

Mechanism of hot flashes

Treatment recommendations for metastatic colorectal cancer

Prognostic factors in desmoid tumours: an example of translational oncology

Multimodal treatment of desmoid tumours: the significance of local control

Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?

Spinal cord astrocytoma: multidisciplinary experience

Keynote webinar | Spotlight on antibody–drug conjugates in cancer